MX2021005214A - Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol. - Google Patents

Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol.

Info

Publication number
MX2021005214A
MX2021005214A MX2021005214A MX2021005214A MX2021005214A MX 2021005214 A MX2021005214 A MX 2021005214A MX 2021005214 A MX2021005214 A MX 2021005214A MX 2021005214 A MX2021005214 A MX 2021005214A MX 2021005214 A MX2021005214 A MX 2021005214A
Authority
MX
Mexico
Prior art keywords
pyrido
tetrahydro
indole
estrogenic drugs
disorders
Prior art date
Application number
MX2021005214A
Other languages
English (en)
Inventor
David C Myles
Peter J Kushner
Cyrus L Harmon
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Publication of MX2021005214A publication Critical patent/MX2021005214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona compuestos tetrahidro-1H-pirido[3,4-b] indol o una sal, solvente, hidrato, profármaco, estereoisómero, tautómero, rotámero, N-óxido y/o un derivado sustituido, farmacéuticamente aceptable, u opcionalmente en una composición farmacéutica, para la modulación de desórdenes mediados por estrógeno, u de otros desórdenes como se describe más completamente en este documento.
MX2021005214A 2015-10-01 2018-03-28 Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol. MX2021005214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
MX2021005214A true MX2021005214A (es) 2021-06-18

Family

ID=58427985

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003929A MX2018003929A (es) 2015-10-01 2016-09-29 Fármacos anti-estrogénicos tetrahidro-1h-pirido [3,4-b] indol.
MX2021005214A MX2021005214A (es) 2015-10-01 2018-03-28 Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003929A MX2018003929A (es) 2015-10-01 2016-09-29 Fármacos anti-estrogénicos tetrahidro-1h-pirido [3,4-b] indol.

Country Status (24)

Country Link
US (4) US10292971B2 (es)
EP (2) EP3355884B1 (es)
JP (3) JP6776348B2 (es)
KR (1) KR20180071274A (es)
CN (2) CN113248494A (es)
AU (3) AU2016331065B2 (es)
BR (2) BR112018006121B1 (es)
CA (1) CA3000410A1 (es)
CL (1) CL2018000827A1 (es)
CY (1) CY1124669T1 (es)
DK (1) DK3355884T3 (es)
ES (1) ES2881398T3 (es)
HR (1) HRP20211124T1 (es)
HU (1) HUE055321T2 (es)
IL (3) IL310489A (es)
LT (1) LT3355884T (es)
MX (2) MX2018003929A (es)
PL (1) PL3355884T3 (es)
PT (1) PT3355884T (es)
RS (1) RS62133B1 (es)
RU (2) RU2745742C1 (es)
SI (1) SI3355884T1 (es)
UA (1) UA122346C2 (es)
WO (1) WO2017059139A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102559719B1 (ko) 2014-12-18 2023-07-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
RU2734501C2 (ru) * 2016-02-05 2020-10-19 Инвентисбио Инк. Селективные ингибиторы эстрогеновых рецепторов и их применение
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
ES2751902T3 (es) 2016-10-24 2020-04-02 Astrazeneca Ab Derivado de 6,7,8,9-tetrahidro-3H-pirazolo[4,3-f]isoquinolina útil en el tratamiento del cáncer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
ES2766249T3 (es) 2017-01-30 2020-06-12 Astrazeneca Ab Moduladores del receptor de estrógeno
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
PE20211207A1 (es) 2018-06-21 2021-07-05 Hoffmann La Roche Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso
WO2020132785A1 (en) 2018-12-24 2020-07-02 Inventisbio Shanghai Ltd. Novel salts of selective estrogen receptor degraders
JP2022532342A (ja) * 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
CA3144791A1 (en) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4114391A4 (en) * 2020-03-06 2024-05-22 Olema Pharmaceuticals, Inc. METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators
CN116744920A (zh) * 2021-02-08 2023-09-12 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4366734A1 (en) * 2021-07-08 2024-05-15 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2024039858A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024039860A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039861A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024076626A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024124182A1 (en) * 2022-12-09 2024-06-13 Olema Pharmaceuticals, Inc. Dosage forms of an estrogen receptor antagonist

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ATE247114T1 (de) * 1994-09-12 2003-08-15 Lilly Co Eli Serotonergische modulatoren
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
JP2004502734A (ja) 2000-07-06 2004-01-29 ワイス 一酸化窒素シンターゼ活性の増強方法
CN1468110A (zh) 2000-07-06 2004-01-14 惠氏公司 他汀类、雌激素药物以及任选雌激素的联合应用
CN1450913A (zh) 2000-07-06 2003-10-22 惠氏公司 二膦酸酯、雌激素药物以及任选雌激素的联合应用
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
DK1318837T3 (da) 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2002323098A1 (en) 2001-08-11 2003-03-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
EP1720862A1 (en) 2004-02-03 2006-11-15 Eli Lilly And Company Kinase inhibitors
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
SG151267A1 (en) * 2004-03-15 2009-04-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
EP1846397A1 (en) 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
PL2434891T3 (pl) 2009-05-27 2020-12-28 Ptc Therapeutics, Inc. Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
AU2011347718B2 (en) * 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
ES2654161T3 (es) 2013-05-28 2018-02-12 Astrazeneca Ab Compuestos químicos
AU2014281511A1 (en) * 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
RU2015152171A (ru) 2013-06-19 2017-07-25 Серагон Фармасьютикалз, Инк. Азетидиновые модуляторы эстрогеновых рецепторов и их применения
BR112017008410A2 (pt) * 2014-10-23 2017-12-19 Oy Mtg Meltron Ltd aparelho de iluminação para áreas perigosas
GB2567981B (en) * 2014-10-31 2019-10-30 Karsten Mfg Corp Grooves of golf club heads and methods to manufacture grooves of golf club heads
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
KR102559719B1 (ko) * 2014-12-18 2023-07-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
EP3233818A1 (en) * 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
ES2751902T3 (es) 2016-10-24 2020-04-02 Astrazeneca Ab Derivado de 6,7,8,9-tetrahidro-3H-pirazolo[4,3-f]isoquinolina útil en el tratamiento del cáncer
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
ES2932867T3 (es) 2018-07-12 2023-01-27 Lilly Co Eli Degradadores selectivos de los receptores de estrógenos

Also Published As

Publication number Publication date
CL2018000827A1 (es) 2018-09-28
BR122023020677A2 (pt) 2023-12-12
CN108366996A (zh) 2018-08-03
AU2023202620A1 (en) 2023-05-18
RU2745742C1 (ru) 2021-03-31
PT3355884T (pt) 2021-07-26
CN108366996B (zh) 2021-04-09
BR112018006121A2 (pt) 2018-10-23
AU2016331065A1 (en) 2018-04-26
IL286518B2 (en) 2024-06-01
IL286518B1 (en) 2024-02-01
MX2018003929A (es) 2018-11-22
JP6776348B2 (ja) 2020-10-28
CY1124669T1 (el) 2022-07-22
AU2016331065B2 (en) 2021-04-29
CA3000410A1 (en) 2017-04-06
HUE055321T2 (hu) 2021-11-29
US11229630B2 (en) 2022-01-25
AU2021206861B2 (en) 2023-02-02
IL258363A (en) 2018-05-31
LT3355884T (lt) 2021-07-26
US10624878B2 (en) 2020-04-21
PL3355884T3 (pl) 2021-11-29
JP2018530549A (ja) 2018-10-18
CN113248494A (zh) 2021-08-13
ES2881398T3 (es) 2021-11-29
SI3355884T1 (sl) 2021-11-30
BR112018006121B1 (pt) 2024-01-23
JP2023087106A (ja) 2023-06-22
US20190247372A1 (en) 2019-08-15
EP3355884A4 (en) 2019-06-05
US11672785B2 (en) 2023-06-13
EP3355884A1 (en) 2018-08-08
UA122346C2 (uk) 2020-10-26
EP3912680A1 (en) 2021-11-24
US20210059991A1 (en) 2021-03-04
US20180289679A1 (en) 2018-10-11
US20220370421A1 (en) 2022-11-24
US20240131013A1 (en) 2024-04-25
AU2021206861A1 (en) 2021-08-12
EP3355884B1 (en) 2021-04-28
IL258363B (en) 2021-10-31
HRP20211124T1 (hr) 2021-10-15
IL286518A (en) 2021-10-31
WO2017059139A1 (en) 2017-04-06
JP2021001231A (ja) 2021-01-07
DK3355884T3 (da) 2021-08-02
US10292971B2 (en) 2019-05-21
JP7277424B2 (ja) 2023-05-19
RS62133B1 (sr) 2021-08-31
KR20180071274A (ko) 2018-06-27
RU2021107754A (ru) 2021-04-01
IL310489A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
MX2021005214A (es) Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol.
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA033689B9 (ru) Ингибиторы g12c kras
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
PH12016501903B1 (en) Novel fused imidazobenzothiazole compounds
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
WO2015127284A3 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
HK1257129A1 (zh) 含有吲哚衍生物的藥物組合物、其製備方法和用途
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.